Partner Awards

ALK-Positive Lung Cancer Transformational Research Awards

To date, the success of immunotherapy in lung cancer has been restricted to those lung cancer subtypes that do not have driver mutations such as ALK gene rearrangements. The ALK-positive projects selected are designed to learn how immunotherapy can be used for ALK-positive patients. Specifically, they aim to determine why immunotherapy has not been successful in treating ALK-positive lung cancer and to test new immunotherapy approaches in ALK-positive lung cancer.

Year of award: 2018